🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Cambridge
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Cambridge

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2846 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 20 Sep 2026, 03:15 UTC
2846
Studies in scope
industry-sponsored, all four open statuses
1377
Recruiting now
open to new participants
539
Lead sponsors
across recruiting studies
Top sites
London 2003 Manchester 674 Birmingham 469 Glasgow 437 Cambridge 416
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca64 Merck Sharp & Dohme LLC26 Hoffmann-La Roche15 Janssen Research & Development, LLC15 AbbVie13
Site city
London2003 Manchester674 Birmingham469 Glasgow437 Cambridge416
All 426 cities
Target enrolment
to
416 of 2846 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Active, closed
A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
NCT06812325Thyroid Eye Disease (TED)
Viridian Therapeutics, Inc.
Phase 3
320
Bristol, Cambridge, London, Newcastle
2025-02-03
Recruiting
A Study to Understand How Cardiac Surgery-associated Acute Kidney Injury Develops in Participants Who Undergo Heart Surgery With the Use of Heart-lung Machine
NCT06772025Cardiac Surgery-associated Acute Kidney Injury
Bayer
Not applicable
200
Cambridge, Harefield, London
2025-02-03
Recruiting
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
NCT06679881Hereditary Angioedema (HAE)
Pharvaris Netherlands B.V.
Phase 3
170
Birmingham, Brighton, Bristol, Cambridge, Frimley, London, Oxford, Plymouth
2025-02-01
Recruiting
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Bicara Therapeutics
Phase 2/3
650
Aberdeen, Birmingham, Cambridge, Glasgow, Leeds, Liverpool, London, Manchester
2025-01-28
Active, closed
HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)
NCT06634420Hereditary Angioedema
Intellia Therapeutics
Phase 3
80
Cambridge
2025-01-15
Recruiting
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
NCT06743126Melanoma, Cutaneous Malignant
Immatics US, Inc.
Phase 3
360
Cambridge, Glasgow, London, Manchester, Oxford, Southampton
2025-01-14
Active, closed
A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
NCT06618001Leukemia, Myeloid, Acute, Myelodysplastic Neoplasms
Janssen Research & Development, LLC
Phase 1
64
Cambridge, London, Manchester
2025-01-14
Active, closed
A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine
NCT06619509Solid Tumours
Boehringer Ingelheim
Phase 2
90
Cambridge, London
2024-12-30
Recruiting
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
NCT06727604Graves' Disease
Immunovant Sciences GmbH
Phase 2
240
Birmingham, Bristol, Coventry, London, Cambridge, Cardiff, Edinburgh, Huddersfield
2024-12-17
Active, closed
A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease
NCT06734234Kidney Disease
GlaxoSmithKline
Phase 1
86
Cambridge, Exeter, London, Newcastle upon Tyne
2024-12-11
Active, closed
Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy
NCT06681324Crohn's Disease
AstraZeneca
Phase 2
24
Birmingham, Cambridge, London
2024-12-11
Active, closed
Nipocalimab in Moderate to Severe Sjogren's Disease
NCT06741969Sjogrens Syndrome
Janssen Research & Development, LLC
Phase 3
655
Cambridge, Doncaster, Greater London, Leeds, Liverpool, London, Peterborough, Swindon
2024-12-04
Active, closed
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
NCT06669754Hereditary Angioedema (HAE)
Pharvaris Netherlands B.V.
Phase 3
81
London, Birmingham, Bristol, Cambridge, Frimley, Leeds, Oxford, Plymouth
2024-12-01
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
NCT06627647Non-squamous Non-small Cell Lung Cancer
AstraZeneca
Phase 3
1,160
Aberdeen, Cambridge, Edinburgh, Exeter, Greater London, London, Manchester, Newcastle upon Tyne
2024-11-27
Active, closed
Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis
NCT06444113Multiple Sclerosis
Novartis Pharmaceuticals
Phase 4
24
Cambridge, London, Oxford, Salford
2024-11-25
Recruiting
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
NCT06672549Obesity, Overweight
Eli Lilly and Company
Phase 3
125
Barnsley, Bristol, Cambridge, Dundee, Harrow, Hull, Liverpool
2024-11-18
Active, closed
A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK4528287 in Healthy Participants
NCT06681181Colitis, Ulcerative
GlaxoSmithKline
Phase 1
48
Cambridge
2024-11-18
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738Non-small Cell Lung Cancer
AstraZeneca
Phase 3
1,160
Aberdeen, Cambridge, Edinburgh, Exeter, Greater London, London, Manchester, Newcastle upon Tyne
2024-11-18
Active, closed
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
NCT06422884Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease
Endeavor Biomedicines, Inc.
Phase 2
213
Belfast, Birmingham, Cambridge, Edinburgh, Exeter, Leicester, London, Londonderry
2024-11-15
Active, closed
A Study of Mosliciguat in PH-ILD
NCT06635850Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases
Pulmovant, Inc.
Phase 2
135
Cambridge, London, Clydebank
2024-10-29
Recruiting
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
NCT06649110Healthy Volunteers, Pulmonary Arterial Hypertension
Novartis Pharmaceuticals
Phase 1/2
232
Sheffield, Cambridge, London
2024-10-24
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786Colorectal Neoplasms
Janssen Research & Development, LLC
Phase 3
1,000
Birmingham, Cambridge, Edinburgh, Hull, Leeds, London, Northwood, Sutton
2024-10-18
Active, closed
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
NCT06637371Asthma
Amgen
Phase 1
21
Cambridge, London, Manchester
2024-10-16
Recruiting
A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
NCT06585449Huntington's Disease
Alnylam Pharmaceuticals
Phase 1
66
Birmingham, Cambridge, Cardiff, Glasgow, Greater Manchester, London, Oxford, Plymouth
2024-10-14
Active, closed
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
NCT06388564Chronic Graft-versus-host-disease
Incyte Corporation
Phase 2
130
Birmingham, Cambridge, Cardiff, Glasgow, Leeds, Liverpool
2024-10-11
Rows per page Showing 126–150 of 416
Previous 4 5 6 7 8 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-uk/city/cambridge

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.